Trenzyme receives approval for biosafety level 2 (BSL-2)
The Konstanz (Germany)-based Trenzyme GmbH just received approval for their biosafety level 2 (BSL-2) facility. Trenzyme is a biotech company offering a wide range of services in research and development for their customers. The company's core strengths are their cell line development as well as protein expression and purification businesses. Trenzyme offers exceptionally fast cell line development and employs expression systems from bacteria and yeast to insect and mammalian cells. Equally, the full range of molecular biology services is also available to their customers. By expanding their facility to accomodate BSL-2-classified projects Trenzyme once more guarantees their partners to stay ahead of the class.
Most read news
Topics
Organizations
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

A low-calorie diet alters the gut microbiome and delays immune aging
Hand,_foot_and_mouth_disease
ITI Life Sciences signs commercialisation licence agreements with Edinburgh Instruments and Almac Sciences (Scotland) Ltd
Novozymes prevails in patent trial against Danisco

Novel biomarker score could help measure adherence to Mediterranean diet - New evidence suggests Mediterranean diet may reduce type 2 diabetes risk more than previously thought
ProtAffin AG signs manufacturing contract for PA401 with CMC Biologics A/S
RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
The OakLabs GmbH receives High-Tech Gründerfonds seed funding for intelligent breeding methods
City_of_Hope_National_Medical_Center
Leigh's_disease
Hepatopulmonary_syndrome
